Insider Transactions in Q4 2020 at Catalent, Inc. (CTLT)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2020
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
13,662
-11.51%
|
$1,393,524
$102.88 P/Share
|
|
Dec 21
2020
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,662
+10.18%
|
$409,860
$30.23 P/Share
|
|
Dec 17
2020
|
John R Chiminski Executive Chair |
SELL
Bona fide gift
|
Direct |
10,000
-5.76%
|
-
|
|
Nov 23
2020
|
Peter Zippelius Director |
SELL
Open market or private sale
|
Indirect |
5,392,280
-100.0%
|
$533,835,720
$99.26 P/Share
|
|
Nov 23
2020
|
Peter Zippelius Director |
BUY
Conversion of derivative security
|
Indirect |
5,392,280
+50.0%
|
$264,221,720
$49.54 P/Share
|
|
Nov 11
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
2,425
-3.19%
|
$242,500
$100.99 P/Share
|
|
Oct 29
2020
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+12.48%
|
-
|
|
Oct 29
2020
|
J Martin Carroll |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+10.5%
|
-
|
|
Oct 29
2020
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+15.79%
|
-
|
|
Oct 29
2020
|
Rolf A Classon |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+6.46%
|
-
|
|
Oct 29
2020
|
Christa Kreuzburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+19.51%
|
-
|
|
Oct 29
2020
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+15.79%
|
-
|
|
Oct 29
2020
|
Donald E Morel Jr |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+3.86%
|
-
|
|
Oct 29
2020
|
Gregory T Lucier |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+9.73%
|
-
|
|
Oct 29
2020
|
Jack L Stahl |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+6.46%
|
-
|
|
Oct 29
2020
|
Peter Zippelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+24.85%
|
-
|
|
Oct 28
2020
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,249
+13.89%
|
-
|
|
Oct 23
2020
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Payment of exercise price or tax liability
|
Direct |
425
-2.7%
|
$39,950
$94.02 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
5,510
-0.99%
|
$512,430
$93.42 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,515
-5.5%
|
$884,895
$93.15 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,025
+7.83%
|
$420,700
$28.2 P/Share
|
|
Oct 14
2020
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
2,985
-4.22%
|
$277,605
$93.54 P/Share
|
|
Oct 12
2020
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
1,680
-8.9%
|
$157,920
$94.99 P/Share
|
|
Oct 07
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
15,928
-29.2%
|
$1,449,448
$91.5 P/Share
|
|
Oct 07
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Payment of exercise price or tax liability
|
Direct |
23,414
-30.03%
|
$2,130,674
$91.5 P/Share
|
|
Oct 07
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Exercise of conversion of derivative security
|
Direct |
39,342
+8.17%
|
$1,416,312
$36.28 P/Share
|
|
Oct 04
2020
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-0.62%
|
$20,400
$85.88 P/Share
|
|
Oct 02
2020
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
182,231
-26.25%
|
$15,489,635
$85.66 P/Share
|
|
Oct 02
2020
|
John R Chiminski Executive Chair |
SELL
Payment of exercise price or tax liability
|
Direct |
86,251
-10.86%
|
$7,417,586
$86.01 P/Share
|
|
Oct 02
2020
|
John R Chiminski Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
138,135
+14.48%
|
$3,867,780
$28.2 P/Share
|
|
Oct 02
2020
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
4,359
-7.3%
|
$370,515
$85.65 P/Share
|
|
Oct 02
2020
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
5,200
-19.81%
|
$436,800
$84.94 P/Share
|
|
Oct 02
2020
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
7,347
+21.87%
|
$264,492
$36.02 P/Share
|